Calithera Biosciences Inc

Calithera Biosciences Inc

  • Price (USD)3.10
  • Today's Change0.17 / 5.80%
  • Shares traded2.00m
  • 1 Year change-55.07%
  • Beta1.5609
Data delayed at least 15 minutes, as of Jan 22 2021 21:00 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

  • Revenue in USD (TTM)0.00
  • Net income in USD-89.30m
  • Incorporated2010
  • Employees93.00
  • Location
    Calithera Biosciences Inc343 Oyster Point Blvd # 200SOUTH SAN FRANCISCO 94080-1913United StatesUSA
  • Phone+1 (650) 870-1000
  • Fax+1 (302) 655-5049
  • Websitehttp://www.calithera.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Exicure Inc16.78m-21.96m203.24m48.00--2.77--12.11-0.267-0.2670.19760.84180.1814--516.40578,724.10-23.73---26.75-------130.87------0.1835--998.31---17.36------
Abeona Therapeutics Inc7.00m-84.84m208.88m88.00--1.56--29.84-1.04-1.040.08381.360.0463--2.0079,545.45-56.16-29.61-69.78-32.36-----1,211.96-3,412.06---33.940.015---100.00---34.61------
Idera Pharmaceuticals Inc0.00-87.24m209.74m36.00---------2.80-2.800.00-0.9210.00----0.00-152.30-60.33-187.44-70.81-------1,383.99---328.74----118.7381.76-41.21---60.14--
Sesen Bio Inc11.24m-41.09m213.41m25.00------18.99-0.3841-0.38410.10-0.13390.0984----449,440.00-35.85-48.95-39.06-52.68-----364.37-642.70-------------219.06---0.1464--
OptiNose Inc43.85m-100.92m214.05m102.00--7.73--4.88-2.20-2.200.95220.53150.26541.073.08429,911.80-61.09---78.51--83.23---230.14--3.76-7.990.7914--390.18---3.18------
Calithera Biosciences Inc0.00-89.30m218.73m93.00--1.78-----1.39-1.390.001.740.00----0.00-60.74-40.33-69.84-45.98-------503.98----0.00---100.00---64.49---58.31--
Evolus Inc55.41m-66.83m223.42m125.00--6.37--4.03-2.02-2.021.681.040.27811.975.96235,787.20-33.54---37.15--73.55---120.60--10.03-7.480.7912-------92.11------
Protara Therapeutics Inc0.00-26.78m223.68m8.00--1.08-----7.34-7.340.0018.500.00----0.00-25.68-51.50-26.38-57.38------------0.0019------27.68---20.69--
Eton Pharmaceuticals Inc417.00k-22.98m223.98m5.00--139.87--537.11-1.18-1.180.02140.06610.0335----24,529.41-184.56---223.36---6.71---5,510.55--2.51-35.360.8347------50.79------
Axcella Health Inc0.00-57.10m224.87m66.00--2.50-----2.14-
Tyme Technologies Inc0.00-28.36m226.50m18.00--15.62-----0.2333-0.23330.000.11140.00----0.00-142.92---192.92-------------13.180.0119------33.30------
Milestone Pharmaceuticals Inc0.00-59.59m228.74m28.00--1.86-----2.22-
Eledon Pharmaceuticals Inc0.00-21.05m228.76m7.00--0.9477-----22.51-22.510.0016.870.00----0.00-20.26-64.74-21.05-70.42------------0.00-------13.84------
ADMA Biologics Inc40.30m-66.90m229.75m313.00--3.05--5.70-0.8653-0.86530.52480.79650.24590.97925.90128,756.40-40.82-60.76-45.18-70.31-33.67-39.80-166.01-224.624.24-4.980.5762--72.7937.7626.56--10.41--
Evofem Biosciences Inc278.00k-114.43m230.02m53.00--5.72--827.42-1.93-1.930.00470.49470.0037--0.28435,245.28-151.24-239.25-323.65-402.0821.94---41,161.15--1.51-2.460.5444------36.37--55.43--
Neubase Therapeutics Inc0.00-17.38m233.63m3.00--7.46-----0.9026-0.90260.001.350.00-------74.01-87.20-84.14-100.52-----------63.090.0044------33.47--31.12--
Data as of Jan 22 2021. Currency figures normalised to Calithera Biosciences Inc's reporting currency: US Dollar USD

Institutional shareholders

58.55%Per cent of shares held by top holders
HolderShares% Held
PRIMECAP Management Co.as of 30 Sep 202010.06m14.26%
Federated Global Investment Management Corp.as of 30 Sep 20207.45m10.56%
BVF Partners LPas of 30 Sep 20204.59m6.50%
BlackRock Fund Advisorsas of 30 Sep 20204.30m6.10%
Point72 Asset Management LPas of 30 Sep 20203.73m5.28%
The Vanguard Group, Inc.as of 30 Sep 20203.37m4.77%
Great Point Partners LLCas of 30 Sep 20202.92m4.14%
Wellington Management Co. LLPas of 30 Sep 20202.11m3.00%
Dimensional Fund Advisors LPas of 30 Sep 20201.49m2.11%
SSgA Funds Management, Inc.as of 30 Sep 20201.29m1.83%
More ▼
Data from 30 Sep 2020 - 30 Sep 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.